IgA nephropathy trials in Israel

4 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

• Phase 3Taking people
  A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy

  Where

  Ashkelon, Jerusalem, Petah Tikva

  Age

  18 years to 100 years

  People

  540 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT04557462 · EU 2023-508690-92-00
• Phase 3Taking people
  Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgAN

  Where

  Beersheba, Haifa, Jerusalem, Petah Tikva

  Age

  2 years to 18 years

  People

  31 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT06994845
• Phase 2Taking people
  Study to Evaluate the Impact of Iptacopan on Top of SOC on Biopsy Changes in Kidneys of Adult Patients With IgAN

  Where

  Ashdod, Hadera, Haifa, Nahariya

  Age

  18 years to 99 years

  People

  20 worldwide

  Run by

  Novartis Pharmaceuticals

  See details and how to joinNCT06797518
• Phase 2/3Enrolling by invitation
  Trial of Sibeprenlimab in the Treatment of Immunoglobulin A Nephropathy (IgAN)

  Where

  Ashkelon, Kfar Saba, Nahariya, Petach Tiqwa

  Age

  18 years and over

  People

  600 worldwide

  Run by

  Otsuka Pharmaceutical Development & Commercialization, Inc.

  See details and how to joinNCT05248659